SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to reports of considering an all-cash bid for Warner Bros. Discovery, which the community is largely viewing as a bullish signal for avoiding dilution and indicating strong upcoming earnings. This comes amid an escalating takeover battle with Paramount, while many anticipate a pre-earnings rally or short squeeze ahead of its highly awaited report.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending as it navigates an escalating takeover battle, with its board reportedly favoring Netflix's acquisition proposal over Paramount Skydance's (PSKY) all-cash offer, despite a personal financing guarantee. The community is buzzing with debate, weighing PSKY's perceived superior value and the potential for a significantly higher bid from either contender to secure market dominance in the evolving media landscape. Shareholders are closely watching for definitive developments in this strategic consolidation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is a hot topic as investors analyze unaudited Q4 revenue and 2026 guidance for its multiple sclerosis treatment, Briumvi, ahead of an anticipated presentation at a major healthcare conference. The community is buzzing about Briumvi's strong market adoption and competitive advantages, further bolstered by recent issues impacting rival treatments. Despite operational strength, widespread discussion centers on the stock's valuation and the ongoing debate between its fundamental growth and market sentiment.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amid a wave of analyst downgrades and intensified debate around increasing AI-driven competition, notably from Apple's new creative software suite. While many investors see the stock as deeply undervalued given strong fundamentals and ongoing share buybacks, others express deep concern that AI advancements will erode Adobe's long-term market dominance. The community is sharply divided between those who believe the current dip is a prime buying opportunity and those who view it as a signal of structural weakness for the software giant.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics (CADL) is trending amid intense community speculation regarding an imminent major partnership or acquisition, with Novartis frequently mentioned as a potential suitor. This excitement is amplified by the upcoming J.P. Morgan Healthcare Conference, a hub for anticipated biopharma M&A, and recent FDA flexibility on CMC requirements, which could accelerate the BLA submission for its lead prostate cancer drug, CAN-2409. The community is actively debating the company's current low valuation against its promising clinical data, eagerly anticipating a transformative deal or further clarity on its expedited regulatory path.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as a high-leverage play on the Injective (INJ) ecosystem, which is gaining significant attention for its robust developer activity, strong revenue performance, and institutional interest, including staked ETF filings. The community is actively discussing NONJA's unique resilience, high burned liquidity, and dedicated base, positioning it for substantial upside as Injective's undervalued chain continues to grow.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging amid positive financial outlook revisions and ongoing regulatory progress for its next-generation COVID and flu vaccines, complemented by funding for a pandemic flu trial. Community discussion centers on the company's perceived undervaluation and the long-term potential of its diverse mRNA pipeline, particularly in oncology, with many anticipating a substantial short squeeze. This renewed interest highlights a broader re-evaluation of Moderna's platform capabilities within the evolving biotech landscape.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is at the center of a contentious takeover bid for Warner Bros. Discovery, persistently pushing its all-cash offer while challenging Netflix's rival deal. The community is intensely debating WBD's repeated rejections, with many questioning if the board is prioritizing personal interests over shareholder value, especially as PSKY escalates with a lawsuit seeking financial transparency and plans to nominate new directors. This ongoing media M&A drama is further complicated by anticipated regulatory scrutiny for the alternative Netflix bid.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending due to an imminent shareholder vote on a massive proposed increase in authorized shares and executive compensation. Community perspectives are sharply divided, with significant retail investor frustration over perceived dilution and the stock's underperformance relative to Ethereum's recent strength. This crucial decision, alongside ongoing concerns about market manipulation and the company's strategy to expand its Ethereum treasury, is fueling widespread debate and anxiety among shareholders.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending due to a significant sell-off, with community discussion centering on ongoing CEO stock sales and potential competitive impacts from new AI agents like Anthropic's Claude Cowork. Despite this, many investors view the sharp dip as a strong buying opportunity, banking on the company's solid fundamentals, evolving leadership in agentic automation, and strategic partnerships to drive future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have received an average rating of "Hold" from the fourteen research firms that are covering the stock, Marketbeat.com reports. One...

Promising Mid Cap Stocks To Watch Now - December 10th

ProShares UltraPro Short QQQ, Direxion Daily TSLA Bull 2X Shares, Rigetti Computing, Akero Therapeutics, AltC Acquisition, D-Wave Quantum, and Ondas are the seven Mid Cap stocks to watch today...

Best Medical Stocks To Follow Now - December 10th

Eli Lilly and Company, Akero Therapeutics, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies...

Akero Therapeutics' (AKRO) "Overweight" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated an "overweight" rating on shares of Akero Therapeutics in a report on Wednesday...

Stempoint Capital LP Reduces Stock Position in Akero Therapeutics, Inc. $AKRO

Stempoint Capital LP trimmed its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 25.2% in the second quarter, according to its most recent filing with the Securities and...

Best Medical Stocks To Watch Now - December 9th

Eli Lilly and Company, Akero Therapeutics, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Vivo Capital LLC Buys 233,521 Shares of Akero Therapeutics, Inc. $AKRO

Vivo Capital LLC increased its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 116.1% in the second quarter, according to its most recent 13F filing with the Securities and...

Akero Therapeutics, Inc. $AKRO Stock Holdings Lessened by Marshall Wace LLP

Marshall Wace LLP reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 11.8% in the second quarter, according to the company in its most recent disclosure with the Securities...

JPMorgan Chase & Co. Sells 18,890 Shares of Akero Therapeutics, Inc. $AKRO

JPMorgan Chase & Co. reduced its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 5.7% in the second quarter, according to the company in its most recent filing with the Securities...

Akero Therapeutics, Inc. $AKRO Position Boosted by Schroder Investment Management Group

Schroder Investment Management Group lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 28.1% in the second quarter, according to its most recent disclosure with the...

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Akero Therapeutics Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.94	--	--	N/A
Q3 '25	-$0.96	--	--	N/A
Q2 '25	-$0.92	-$0.86	6.23%	BEAT
Q1 '25	-$0.96	-$0.90	6.18%	BEAT
Q4 '24	-$1.16	-$0.99	14.75%	BEAT

AKRO
Akero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AKRO News

AKROAkero Therapeutics Inc